Biotech & Pharma Due Diligence Best Practices, Pitfalls & Checklist

19th January 2026
For over fifteen years, Alacrita has been an expert resource for due diligence and valuation services covering pharmaceuticals and biotechnology. This paper shares some of the insights we've learned...
Learn More

Pharma Due Diligence: Guilty Until Proven Innocent

19th January 2026
Introduction Why the Burden Falls on You What DD Reveals Proving Innocence in Practice Navigating the Process When the Rule Breaks Down References Pharma Due Diligence: Guilty Until Proven Innocent...
Learn More

Why Later-Stage Draws Dollars and Early Formation Is Lagging

09th January 2026
Executive Summary From Boom to Winter Where the Money Went VCs Pivot to Clinical The Quiet Risk Policy Pressure Where the Opportunity Is The Bottom Line About the Authors References Biotech Venture...
Learn More

When Probability is Fiction: Risk vs. Uncertainty in Biotech Due Diligence

09th January 2026
Introduction What is Risk? What is Uncertainty? Key Differences The Risk Matrix Fallacy Implications for Practice References Risk, Exposure and Uncertainty The concept of risk is central to due...
Learn More

Drug Discovery: Respect the Waves

22nd December 2025
Introduction The True Timeline Case Studies The Valley of Death Therapeutic Variation Clinical Phases The Iteration Pattern What Improves the Odds Persistent Challenges Implications References Drug...
Learn More

Resistance Fighters: Biopharma on the Frontline of the Antibiotic Crisis

02nd December 2025
Executive Summary The Pipeline Small Molecule Development Non-Traditional Approaches Safeguarding Innovation Outlook References Further Whitepapers Contact Us Executive Summary: Warnings of the...
Learn More

Live Biotherapeutic Products: Development, Investment, and Market Dynamics

29th October 2025
Executive Summary Overview Design Philosophy Manufacturing Clinical Development Regulatory Investment Landscape Future Prospects References Further Whitepapers Contact Us Executive Summary...
Learn More

Non-Opioid Chronic Pain Therapeutics Market Analysis

27th August 2025
Market Intelligence Report Life Sciences • Chronic Pain August 2025 Chasing Rainbows: Navigating the $84B Non-Opioid Chronic Pain Therapeutics Market Comprehensive analysis of non-opioid therapeutics...
Learn More

Slim chance or fat profit: will the obesity market just keep on growing?

21st July 2025
Introduction Since the mid-twentieth century, the World Health Organization (WHO) has recognized "obesity" as a stand-alone, chronic, non-communicable and preventable disease that remains a major,...
Learn More

Pharmaceutical Disruption: Are Compounding Pharmacies a Friend or Foe?

23rd January 2025
1. Introduction In the dynamic landscape of drug development and distribution, compounding pharmacies have come to play an important role in addressing unique patient needs. However, their presence...
Learn More

Cancer Immunotherapy: Can Antifibrotics Unlock the Door to Cold Tumors?

03rd January 2025
Introduction Cancer immunotherapy has revolutionized the landscape of cancer treatment, shifting the paradigm from non-specific, cytotoxic approaches to strategies that harness the body’s immune...
Learn More

Senotherapy: The battle for quality vs quantity of life

12th September 2024
Introduction By the year 2050, more than 2 billion individuals will be over age 60.1 At the same time, advances in healthcare and standards of living have resulted in an increase in lifespan for...
Learn More
1 2 3 4
Next

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2009-25 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.